期刊
INFLAMMOPHARMACOLOGY
卷 31, 期 3, 页码 1107-1115出版社
SPRINGER BASEL AG
DOI: 10.1007/s10787-023-01163-7
关键词
Alzheimer's disease; Metformin; Insulin resistance
There is an association between type 2 diabetes mellitus and Alzheimer's disease, as both can increase the risk of developing Alzheimer's disease. Insulin resistance inhibits neuronal insulin receptors, impairing amyloid beta clearance and leading to the development of Alzheimer's disease.
Alzheimer's disease (AD) is the most common neurodegenerative disease characterized by extracellular deposition of amyloid beta (A beta) leading to cognitive decline. Evidence from epidemiological studies has shown the association between type 2 diabetes mellitus (T2DM) and the development of AD. T2DM and peripheral insulin resistance (IR) augment the risk of AD with the development of brain IR with inhibition of neuronal insulin receptors. These changes impair clearance of A beta, increase secretion of A beta(1-42), reduce brain glucose metabolism, and abnormal deposition of A beta plaques. Insulin-sensitizing drug metformin inhibits aggregation of A beta by increasing the activity of the insulin-degrading enzyme (IDE) and neprilysin (NEP) levels. Additionally, different studies raised conflicting evidence concerning long-term metformin therapy in T2DM patients, as it may increase the risk of AD or it may prevent the progression of AD. Therefore, the objective of this review was to clarify the beneficial and detrimental effects of long-term metformin therapy in T2DM patients and risk of AD. Evidence from clinical trial studies revealed the little effect of metformin on AD. Various animal studies showed that metformin increases A beta formation by activation of amyloid precursor protein (APP)-cleaving enzymes with the generation of insoluble tau species. Of note, the metformin effect on cognitive function relative to AD pathogenesis is mostly assessed in animal model studies. The duration of metformin therapy was short in most animal studies, this finding cannot apply to the long-term duration of metformin in humans. Therefore, large-scale prospective and comparative studies involving long-term metformin therapy in both diabetic and non-diabetic patients are required to exclude the effect of T2DM-induced AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据